Medicine and Health Sciences Commons^™

Treatment Of Chronic Migraine With Botox (Onabotulinumtoxina): Development, Insights, And Impact, Catherine C. Turkel, Sheena Aurora, Hans-Christoph Diener, David W. Dodick, Richard B. Lipton, Stephen D. Silberstein, Mitchell F. Brin

Department of Jefferson Headache Center papers and presentations

Chronic migraine (CM) is a neurological disease characterized by frequent migraine attacks that prevent affected individuals from performing daily activities of living, significantly diminish quality of life, and increase familial burden. Before onabotulinumtoxinA was approved for CM, there were few treatment options for these seriously disabled patients and none had regulatory approval. The terminology and recognition of CM evolved in parallel with the onabotulinumtoxinA clinical development program. Because there were no globally accepted classification criteria for CM when onabotulinumtoxinA was in development, the patient populations for the trials conducted by Allergan were determined by the Allergan migraine team in collaboration …